chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. Information regarding relevant medical history and concurrent condition were not reported. On 30-NOV-2015 the patient was vaccinated with MMRII (lot # L001336, expiration date 13-JAN-2017, dose and route not reported), which was exposed to temperatures outside of the recommended temperature. No adverse experience had been reported. This is one of several reports received from the same source. Additional information has been requested.
Side effects; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Side effects) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Side effects). At the time of the report, VACCINATION COMPLICATION (Side effects) outcome was unknown.            No concomitant medication reported. No treatment medication reported.
Painful Injection; Accidental Exposure; exposure via skin contact; extra diluent was used; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of swelling (received 1st dose on 8th July 2019).   On 11th September 2019, the patient received the 2nd dose of Shingrix. On 11th September 2019, immediately after receiving Shingrix, the patient experienced injection site pain, inadvertent exposure to vaccine, exposure via skin contact and inappropriate preparation of medication. On an unknown date, the outcome of the injection site pain, inadvertent exposure to vaccine, exposure via skin contact and inappropriate preparation of medication were unknown.   It was unknown if the reporter considered the injection site pain to be related to Shingrix.  Additional details were provided as follows: The patient received 2nd Shingrix dose in her left arm and believed that vaccine was administered incorrectly and that she did not receive full dose of vaccine.  The patient reported that when the pharmacist attempted injection, the needle felt dull and not sharp causing her to jump due the extreme pain from reportedly dull needle. It was reported that clear, cold liquid ran down her arm causing her to suspect full dose was not administered, which led to inadvertent exposure to vaccine, exposure via skin contact. The pharmacist informed that the extra diluent was used while preparing vaccine and that the administered dose was sufficient, which led to inappropriate preparation of medication.  The patient did not experienced reaction to 2nd dose. The patient reported that if the vaccine received intramuscularly. The reporter was unsure of lot number/expiry date.  The reporter desired to know if she was protected from shingles and seeks guidance on either how she can get a refund from pharmacy or  how to receive a 3rd dose without paying for it again.
low grade temperature (not fever) within first 24 hours of vaccine; Myalgia resolved with medication; This is a spontaneous report from a contactable consumer (patient). A patient of unspecified age (reported as 28) and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported.  The patient experienced myalgia resolved with medication, low grade temperature (not fever) within first 24 hours of vaccine on an unspecified date. The outcome of the event myalgia was resolved on an unspecified date, outcome of the other event was unknown.    No follow-up attempts are possible. Information about lot/Batch number cannot be obtained. No further information is expected.
1st dose Oct2021, 2nd not yet; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 79-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in October 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incomplete course of vaccination (Verbatim: 1st dose Oct2021, 2nd not yet). The outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 14-Mar-2023 The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
Patient broke out in hives and 102temp, "M" took child to ER. Was told reaction to one of the seven vaccines she received. Instructed to let child receive only one injection at a time to determine which vaccine she reacted to.
The patient did report swelling, induration and pain at the injection site. The patient  reports onset of headache, fever of 100.6, chills, body aches, night sweats, and malaise within a couple of hours of receiving dose 2 of her Covid 19 vaccine.  Due to how she felt, she went to bed soon after, and slept until the next morning. Upon waking up she noticed resolution of all her symptoms except for night sweats, and malaise.  She continued feeling hot and having night sweats but did not appreciate having a fever.  She also reports  the onset of significant facial swelling, periorbital swelling and swelling of her hands and feet, basically her entire body.  She also reports an onset of "foul smelling" diarrhea.  Her chronic eczematous areas which are her eyebrows, posterior neck, and scalp became more itchy and flaking and peeling.  She developed new areas of eczema and itching over her torso located at her mid axillary areas from her braline down to her waist area.  She also reports the onset of browniish red/ amber colored urine since receiving the vaccine. She continued to flake and peel over her eyebrows and cheeks in  continuously and in large amounts for the next 10 days.  She reports taking no antihistamines, or antipyretics.  She went to urgent care and was treated with 0.5% clobetasol cream which after 2 applications to her face caused a chemical, sun burn like reaction and more severe swelling over her cheeks and periorbital areas.  A photo shows that her left eye was so swollen it was half closed and the skin color was purplish. She returned to urgent care on March 11, 2021 and was prescribed a medrol dose pak.  She started it right away and her facial swelling improved.   On March 13 she came to see me.  with improvement in her swelling, peeling and flaking.   She was noted to have a fever of 101.6, then it was 100.6 after recheck and finally 99.6 before the end of her appointment.   It isn't clear whether her temp decreased because her medrol taken earlier that morning had kicked in or by removing her sweatshirt and being out of the sun allowed her to sweat and decrease her core body temperture to that level.She was asked to continue checking her temp which she reported as 99.8 on March 13, 100.6 on March 14, and 100.5 on March 15.  She has been instructed to check her temp everyday for the next 14 days.  Her urinedipstick showed 1+ bilirubin and ketones with trace blood and all other indicators were negative.  Patient was sent for stat bloodwork to evaluate for possible hemolysis.
Information has been received from a healthcare professional concerning a patient who in 1997 was vaccinated with one dose of varicella virus vaccine live. Subsequently, the patient experienced chickenpox. Medical attention was sought. Three other patients had a similar experience following vaccination with varicella virus vaccine live. No further information is available.
Family of 3 children - all 3 given pediatric dose 1 had turned 12 and should have been given adult dose
Patient developed rash 5/25 around 1:30AM. Patient and cousin were given VARIVAX on 5/13/10 within approximately 1 hour of each other. Cousins are together all the time. Parent not aware of any exposure to chickenpox or shingles.
blisters itching quite a bit on legs and arms/marked swelling and rise on skin surface and theres a head; dime sized red swelling on torso; just don't feel right; blisters itching quite a bit on arms; red welts with blisters that had clear fluid; nausea; fatigue; muscle aches; lightheadedness/dizziness; A spontaneous report was received from a consumer concerning a 67-years-old male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events muscle aches, fatigue, headaches, lightheadedness, dizziness, nausea, red welts with blisters that had clear fluid, blisters itching quite a bit on legs, dime sized red swelling on torso, marked swelling and rise on skin surface and theres a head, just didn't feel right, blisters itching quite a bit on arms.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 5 Feb 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: 057G20A) for prophylaxis of COVID-19 infection.  On 6 Feb 2021, the patient experienced the event(s) muscle aches, fatigue, headaches, lightheadedness, dizziness, nausea.  On an unknown date, the patient experienced the event(s) red welts with blisters that had clear fluid, blisters itching quite a bit on legs, dime sized red swelling on torso, marked swelling and rise on skin surface and theres a head, just didn't feel right, blisters itching quite a bit on arms.  Treatment details included Benadryl.  Action taken with mRNA-1273 in response to the events was not reported.  On 7 Feb 2021 the outcome of event(s), dizziness, nausea was resolved. The outcome of event(s), muscle aches, fatigue, headaches, lightheadedness, red welts with blisters that had clear fluid, blisters itching quite a bit on legs, dime sized red swelling on torso, marked swelling and rise on skin surface and theres a head, just didn't  feel right, blisters itching quite a bit on arms was unknown.
Headache; chills; body aches; nausea; dizziness; I don't feel good; tiredness; cough; chest heaviness; SOB; This is a spontaneous report received from a contactable reporter (Nurse). The reporter is the patient.  A 45-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 06Oct2022 at 10:30 as dose 4 (booster), single (Lot number: Gh9693) at the age of 45 years, in right arm for COVID-19 immunization. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "Known allergies: Environmental" (unspecified if ongoing); "if covid prior vaccination: Yes" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Batch/Lot No: Ff2587), administration date: 30Sep2021, when the patient was 44-year-old, for COVID-19 immunization; Covid-19 vaccine (DOSE 2, SINGLE), for COVID-19 immunization; Covid-19 vaccine (DOSE 1, SINGLE), for COVID-19 immunization. The following information was reported: HEADACHE (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered"; MALAISE (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered", described as "I don't feel good"; DYSPNOEA (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered", described as "SOB"; PAIN (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered", described as "body aches"; CHEST DISCOMFORT (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered", described as "chest heaviness"; CHILLS (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered"; COUGH (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered"; DIZZINESS (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered"; NAUSEA (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered"; FATIGUE (non-serious) with onset 06Oct2022 at 11:00, outcome "not recovered", described as "tiredness". Therapeutic measures were not taken as a result of headache, chills, pain, nausea, dizziness, malaise, fatigue, cough, chest discomfort, dyspnoea.  Additional information: No other vaccine in four weeks. If covid prior vaccination: Yes. If covid tested post vaccination: No.  Follow-up attempts are completed. No further information is expected.
Myalgia  chest pressure, bilateral upper extremity paresthesia/tingling from elbow to hand and fingers and fingers  Narrative:  Employee developed myalgia, chest pressure, bilateral arm tingling, and axilla swelling 2 days after receiving 1st dose of COVID-19 Pfizer vaccine. Myalgia and swelling resolved after 2 days. However, continues to have mild chest pressure and bilateral arm tingling from elbow to fingers. She takes ibuprofen 800 mg once a day for chest pressure. She has been evaluated by primary care provider on 3/20- EKG done, was told she wasn't having a heart attack. She wants to delay her 2nd vaccine (scheduled on 3/24) and has a follow up with PCP on 3/29 to discuss if she should get 2nd dose.
Swelling, cramping, redness, pain, and warmth in left leg. He went to Urgent Care. The ultra sound lady said she saw a small clot. The PA he saw reported the radiologist did not diagnose a clot. The PA cautioned from prescribing any blood thinners for fear of interacting with DM medications (metformin and lisinopril).
Diarrhea Narrative:  Fatigue day after injection that persisted until the following day. Pain over injection site along same timeline. Also had 2x episodes of diarrhea on the same day.
This spontaneous report as received from a other health professional refers to a patient of unknown age. On an unknown date the patient was vaccinated improperly stored dose of PROQUAD lot # N001488, expiration date 12-JUL-2018, single dose, subcutaneous for prophylaxis. Concomitant therapies included sterile diluent (MERCK). There was no adverse effect reported. Administered doses of vaccines experienced the temperature excursion of 7 degrees Fahrenheit for 1 hour. Data logger was involved. There were no previous excursions reported. Additional information is not expected.
Patient given additional dose of varicella with MMR vaccine due o close proximity to and resemblance to MMRV/MMR vaccines in storage area.
The patient was seen in my office on 1/19/21 with complaint of heavy vaginal bleeding.  A CBC was obtained which revealed an H/H of 12.2/36.1 and a platelet count of 1 (not 1K, but 1 platelet!) and this was confirmed on smear review.  She was immediately sent to the Hospital ED and repeat CBC confirmed the critically low platelet count.  She is currently hospitalized and she has received platelet transfusions but her platelet count is still critically low.  She is also receiving steroids and immunoglobulin and is under the care of MD (Heme/Onc)
Swelling on side of tongue, raw, sore gums, chest discomfort, headache.
test shows that I am positive; I have COVID-19; test shows that I am positive; I have COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "test shows that I am positive; I have COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 included Paxlovid.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
patient received booster dose 5 months after second dose instead of 6 months; This spontaneous case was reported by a nurse and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient received booster dose 5 months after second dose instead of 6 months) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 076C21A, 031A21A and 038B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient received booster dose 5 months after second dose instead of 6 months). On 25-Oct-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient received booster dose 5 months after second dose instead of 6 months) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was provided.  No treatment information was provided.   This case was linked to MOD-2021-366716 (Patient Link).
CDC reports: 2 mo had fever to 100 & screaming episode lasting more than 3 hrs following DTP/OPV.
Information has been received from a physician via company representative referring to a female patient of unknown age. No relevant medical history or concurrent conditions were reported. On an unknown date (reported as a few years ago) the patient was vaccinated with a dose of ZOSTAVAX (dose, frequency, route, lot# and expiration date not reported). On an unknown date the patient developed shingles after receiving ZOSTAVAX. The patient sought medical attention in an unspecified way and acyclovir was given as treatment on an unknown date. The outcome of the event was unknown. Causality assessment was not reported. Additional information has been requested.
Fever 102, chills, breathing became shallow, arms numb.  Received Benadryl from MD. MD thought possible panic attack with reaction.
no adverse effect; administered 2 doses of M-M-R II; This spontaneous report was received from office manager refers to a patient of unknown age and gender. No information was provided regarding the patient's pertinent medical history, concomitant medication and drug reactions/allergies. On 27-SEP-2019, the patient may have inadvertently administered 2 doses of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (inappropriate schedule of product administration) for prophylaxis (Therapy type: rHA, Lot # S004118, Expiry date: 11-FEB-2021, strength, dose, frequency, route unspecified). No adverse effect reported. No PQC involved. No further information provided.
He was in medical care for months and now he is in the an assisted care facility because he is still in the wheelchair, he still can not walk; Coma for two months; Guillain-Barre syndrome; Paralysis; He passed out, he fell down; dysthyroid; He passed out, he fell down; He had lost his balance; He couldn't walk; His weight at the time was about a 100, 280 pounds somewhere in that range and knock down to 158; arthritis; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 72 year-old (it's like between 72 and 73) male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) at the age of 72 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Diabetes mellitus" (unspecified if ongoing), notes: Verbatim: Diabetes. The patient took concomitant medications. He was taking stuff now, kind of stuff, now but back then now, he was in pretty good health other than diabetes. Vaccination history included: Bnt162b2 (Dose 1), for COVID-19 Immunization. He had problem after the first shot. The following information was reported: GAIT INABILITY (disability), outcome "unknown", described as "He was in medical care for months and now he is in the an assisted care facility because he is still in the wheelchair, he still can not walk"; COMA (medically significant), outcome "unknown", described as "Coma for two months"; GUILLAIN-BARRE SYNDROME (medically significant), outcome "unknown", described as "Guillain-Barre syndrome"; PARALYSIS (medically significant), outcome "unknown", described as "Paralysis"; SYNCOPE (medically significant), FALL (non-serious), outcome "unknown" and all described as "He passed out, he fell down"; THYROID DISORDER (non-serious), outcome "unknown", described as "dysthyroid"; BALANCE DISORDER (non-serious), outcome "unknown", described as "He had lost his balance"; GAIT DISTURBANCE (non-serious), outcome "unknown", described as "He couldn't walk"; WEIGHT FLUCTUATION (non-serious), outcome "unknown", described as "His weight at the time was about a 100, 280 pounds somewhere in that range and knock down to 158"; ARTHRITIS (non-serious), outcome "unknown", described as "arthritis". It was not really right but when he took the second shot that's when everything went to heck in a handbasket. He had lost his balance. He passed out, he fell down. He couldn't walk and then he, the last time he passed out, he didn't wake up for two months. The patient was in a coma for two months and then had to be reflect to take it twice for the dysthyroid and now was in a care facility because he was still in the wheelchair, he still cannot walk. He was in paralysis and dysthyroid had to be brought back then arthritis and he was in medical care for months. The patient underwent the following laboratory tests and procedures: weight: 100 lbs; 280 lbs; 158 lbs.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient fully vaccinated on 1/21/21 and 2/11/21 with Pfizer. Patient recently hospitalized for COVID19 pneumonia on 1/20/22. Patient presented with shortness of breath and was diagnosed with COVID-19 pneumonia 2 weeks prior to arrival but continued to have symptoms, vaccinated but no booster, admitted for further management, he completed remdesivir and will complete 10-day of dexamethasone as outpatient.    His oxygen need slowly came down , doing well on 1 to 2 L at rest but does have some desaturation on activity and on exertion but symptoms improves and oxygen recovers quickly. Overall inflammatory markers are improving.  Encourage ambulation and progressive strengthening at home. CTA lung is negative for clot on admission.
Pain, Edema, Right arm (immunization site) strength loss, Reynaud Phenomenon, Joint pain. 15 days later pain on the left side arm, one month after presented pain in the low body section. Generalized strength loss, Disability, Fibromyalgia, paresthesia, paresis, chronic pain, chronic fatigue, arthralgia, myalgia, allodynia, costochondritis, headaches,  insomnia, spinal pain, dizziness, nausea, hypotension, gastroesophageal reflux, gastrointestinal disorder, dysautonomia, tachycardia, distal hypothermia, swelling, hair loss, tremors, facial paresis, Tonic-clonic movements, presyncope, Shaking chills, low weight. Current treated with painkillers, anti-convulsives and steroids.